IW-3300

IW-3300 is an investigational small molecule drug developed by Ironwood Pharmaceuticals for the treatment of visceral pain conditions, primarily interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis. It acts as a guanylate cyclase-C (GC-C) agonist, targeting the GC-C receptor predominantly found in the gastrointestinal tract. The drug is administered as a rectal foam and is designed to inhibit pain signaling pathways involved in chronic pelvic and somatic pain. As of 2025, IW-3300 is not approved by regulatory authorities and remains under clinical investigation, with Phase 2 trials ongoing for IC/BPS.